InsidersTradesSigma
V
Vanda Pharmaceuticals Inc.: insider trades · United States · SEC (Form 4)
SEC:vanda-pharmaceuticals-inc-8c3542US·SEC (Form 4)Mcap 378M€Healthcare & Pharma
Discover the full management transaction log of Vanda Pharmaceuticals Inc., a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vanda Pharmaceuticals Inc. has published 40 insider filings. Market capitalisation: €377.7m. The latest transaction was reported on 21 June 2022 — Attribution. Among the most active insiders: Mitchell Stephen Ray. Every trade is free.
40
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€599,888
11 ops.
Sell Volume
Financial data
Analyst consensus
5 analystsStrong buy
7.50 €Target 14.90 €21.00 €
Income statement
Revenue216.1 M€
Gross profit203.1 M€94% margin
Net income−220.5 M€-110.0% margin
Valuation
P/Book1.1x
Beta0.65
Balance sheet & cash
Market cap377.7 M€
Total debt12.6 M€
Free Cash Flow−110.4 M€
Debt / Equity5%
Profitability & ownership
ROE-60.5%
ROA-18.8%
% insiders6.2%
% institutions78.8%
Last declaration on 21 June 2022
Declarations0 total
No declarations found
0 of 0 declarations
About Vanda Pharmaceuticals Inc.
From a competitive standpoint, Vanda operates in highly contested specialty markets where differentiation depends on clinical efficacy, safety profile, intellectual property protection, and commercial execution. The company focuses on niche therapeutic areas rather than mass markets, which can support attractive margins if launches succeed, but also increases binary risk tied to FDA decisions and clinical trial outcomes. Recent 2026 public updates highlighted regulatory progress around imsidolimab and the commercial launch of NEREUS in the United States, while also indicating that certain HETLIOZ-related regulatory requests faced unfavorable outcomes. For investors, Vanda therefore looks like a healthcare name with a high risk/reward profile, highly sensitive to FDA catalysts, Fanapt sales momentum, and the company’s ability to translate its pipeline into recurring revenue.
